

Bryan W Day

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6677774/publications.pdf>

Version: 2024-02-01

40
papers

1,140
citations

394421

19
h-index

414414

32
g-index

43
all docs

43
docs citations

43
times ranked

2302
citing authors

#	ARTICLE	IF	CITATIONS
1	EphA3 Maintains Tumorigenicity and Is a Therapeutic Target in Glioblastoma Multiforme. <i>Cancer Cell</i> , 2013, 23, 238-248.	16.8	193
2	A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma. <i>Scientific Reports</i> , 2019, 9, 4902.	3.3	127
3	Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis. <i>Acta Neuropathologica Communications</i> , 2019, 7, 123.	5.2	73
4	Increased sensitivity to ionizing radiation by targeting the homologous recombination pathway in glioma initiating cells. <i>Molecular Oncology</i> , 2014, 8, 1603-1615.	4.6	61
5	Neurosphere and adherent culture conditions are equivalent for malignant glioma stem cell lines. <i>Anatomy and Cell Biology</i> , 2015, 48, 25.	1.0	49
6	Glioma Surgical Aspirate: A Viable Source of Tumor Tissue for Experimental Research. <i>Cancers</i> , 2013, 5, 357-371.	3.7	48
7	Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2052-2070.	6.4	41
8	Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma. <i>Cancers</i> , 2019, 11, 190.	3.7	39
9	Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy. <i>Clinical and Translational Immunology</i> , 2020, 9, e1191.	3.8	34
10	Nuclear factor one B (<i>NFIB</i>) encodes a subtype-specific tumour suppressor in glioblastoma. <i>Oncotarget</i> , 2016, 7, 29306-29320.	1.8	34
11	ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1. <i>Neuro-Oncology</i> , 2011, 13, 1202-1212.	1.2	32
12	Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells. <i>Cell Death Discovery</i> , 2021, 7, 81.	4.7	31
13	Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. <i>Oncotarget</i> , 2017, 8, 16605-16620.	1.8	30
14	Development and Biological Evaluation of a Photoactivatable Small Molecule Microtubule-Targeting Agent. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 395-400.	2.8	28
15	Comparative study of preclinical mouse models of high-grade glioma for nanomedicine research: the importance of reproducing blood-brain barrier heterogeneity. <i>Theranostics</i> , 2020, 10, 6361-6371.	10.0	27
16	A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4322.	4.1	26
17	EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma. <i>Cancers</i> , 2018, 10, 519.	3.7	25
18	Digenic inheritance of mutations in EPHA2 and SLC26A4 in Pendred syndrome. <i>Nature Communications</i> , 2020, 11, 1343.	12.8	22

#	ARTICLE	IF	CITATIONS
19	A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 39-51.	1.2	22
20	The dystroglycan receptor maintains glioma stem cells in the vascular niche. <i>Acta Neuropathologica</i> , 2019, 138, 1033-1052.	7.7	19
21	Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytoma. <i>Journal of Neuro-Oncology</i> , 2020, 146, 41-53.	2.9	18
22	Direct evidence for transport of RNA from the mouse brain to the germline and offspring. <i>BMC Biology</i> , 2020, 18, 45.	3.8	18
23	Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signalling. <i>Biochemical Pharmacology</i> , 2015, 98, 587-601.	4.4	15
24	Constitutive CHK1 Expression Drives a pSTAT3-CIP2A Circuit that Promotes Glioblastoma Cell Survival and Growth. <i>Molecular Cancer Research</i> , 2020, 18, 709-722.	3.4	15
25	Lower Tubulin Expression in Glioblastoma Stem Cells Attenuates Efficacy of Microtubule-Targeting Agents. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 402-413.	4.9	14
26	MR-guided focused ultrasound increases antibody delivery to nonenhancing high-grade glioma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa030.	0.7	13
27	Q-Cell Glioblastoma Resource: Proteomics Analysis Reveals Unique Cell-States Are Maintained in 3D Culture. <i>Cells</i> , 2020, 9, 267.	4.1	12
28	DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4011.	4.1	12
29	Clinicopathologic significance of nuclear HER4 and phospho-YAP(S ¹²⁷) in human breast cancers and matching brain metastases. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094625.	3.2	11
30	Granule neuron precursor cell proliferation is regulated by NFIX and intersectin 1 during postnatal cerebellar development. <i>Brain Structure and Function</i> , 2019, 224, 811-827.	2.3	10
31	Effectiveness of porous silicon nanoparticle treatment at inhibiting the migration of a heterogeneous glioma cell population. <i>Journal of Nanobiotechnology</i> , 2021, 19, 60.	9.1	9
32	Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors. <i>Pharmacological Research</i> , 2018, 134, 166-178.	7.1	8
33	Simultaneous targeting of DNA replication and homologous recombination in glioblastoma with a polyether ionophore. <i>Neuro-Oncology</i> , 2019, 22, 216-228.	1.2	8
34	MK2 Inhibition Induces p53-Dependent Senescence in Glioblastoma Cells. <i>Cancers</i> , 2020, 12, 654.	3.7	5
35	Transcriptomic Profiling of DNA Damage Response in Patient-Derived Glioblastoma Cells before and after Radiation and Temozolomide Treatment. <i>Cells</i> , 2022, 11, 1215.	4.1	5
36	MerTK activity is not necessary for the proliferation of glioblastoma stem cells. <i>Biochemical Pharmacology</i> , 2021, 186, 114437.	4.4	2

#	ARTICLE	IF	CITATIONS
37	EphA3 As a Target For Monoclonal Antibody Therapy For Acute Leukemia. Blood, 2013, 122, 5013-5013.	1.4	1
38	Immunotherapeutic Targeting of EphA3. Blood, 2014, 124, 3720-3720.	1.4	1
39	Abstract CT101: Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma. , 2021, , .		0
40	Engineering Novel Lentiviral Vectors for Labelling Tumour Cells and Oncogenic Proteins. Bioengineering, 2022, 9, 91.	3.5	0